BOBULSKY SUSAN sold $193K of ADPT

BOBULSKY SUSAN (Chief Commercial Officer, MRD) sold 6,444 shares of Adaptive Biotechnologies Corp (ADPT) at $30.00 ($0.19M total) on 2026-10-06 under a Rule 10b5-1 trading plan.

Original reporting
SEC EDGAR · BOBULSKY SUSAN
Published Oct 8, 2026, 10:52 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Oct 8, 2026, 10:57 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
AlphAI market briefInsider activity
Primary signal
$ADPT
Neutral
medium confidence
Mentioned
$ADPT
Relevance
3/10
AlphAI data visualization · based on SEC EDGAR
Decision brief

The 30-second read

$ADPTNeutralLow
01

Why it matters

This provides incremental transparency on insider liquidity activity but does not indicate a new business, clinical, or regulatory catalyst.

02

Market read

A routine 10b5-1 insider sale is unlikely to drive a sustained repricing by itself.

03

What to watch

10b5-1 plans reduce interpretability; the sale price ($30) may reflect the plan’s execution window rather than a new view on valuation.

Relevance 3/10Novelty 3/10Timing: filed 2026-10-08, sale dated 2026-10-06

Background

The article is an SEC Form 4 insider transaction disclosure for Adaptive Biotechnologies.

Company-level read

Ticker impact

$ADPTNeutralMedium confidence
Context

Adaptive Biotechnologies Form 4 shows CCO Susan Bobulsky sold 6,444 shares at $30.00 on 2026-10-06 under a 10b5-1 plan.

Expected impact

Likely limited near-term impact, with any move more driven by broader biotech sentiment than this transaction.

Evidence & confidence

The filing is a routine insider sale with stated 10b5-1 pre-arrangement; the disclosed dollar value is not large enough to be a standalone fundamental reset.

Market effects

Minimal, as this is company-specific insider activity without disclosed operational or regulatory changes.

None.

None.

Counterpoint

Traders may treat repeated insider sales as a weak confidence signal, especially if paired with other negative company-specific developments not mentioned here.

Key entities

  • Adaptive Biotechnologies Corp

    Subject of the Form 4 insider sale by its Chief Commercial Officer.

  • Susan Bobulsky

    Chief Commercial Officer, MRD, who sold shares under a 10b5-1 plan.

Full insider trading history

This story covers one filing. See everything behind it: every insider buy and sell on record, 10b5-1 plans, late filings, and which officers and directors are trading.

Related articles

$ADPTHigh

Adaptive (ADPT) Q3 2026 Earnings Call Transcript

Adaptive (ADPT) raised its 2026 MRD revenue guidance due to strong clinical volumes and pharma revenue. Q3 saw 46% YOY growth in clinical testing volume, with 41% growth in clinical revenue. The company earned a milestone payment from Pfizer and is advancing its immune medicine separation process. Blood-based testing and community adoption of clonoSEQ increased significantly. U.S. ASP was $1,380 in Q3, with coverage gains in DLBCL and MCL.

$ADPTHigh

Adaptive Biotechnologies Corp (ADPT) Q3 2026 Earnings Call Highlights: First Profitable

Adaptive Biotechnologies (ADPT) reported Q3 2026 revenue of $83.9M, up 39% YoY, with GAAP net income of $2.8M. US ASP was $1,380, flat sequentially. The company expects no GAAP net income for Q4 or the full year. Challenges include Medicare payment structures and CMS rate uncertainties. Management remains confident in long-term pricing strategy and growth, citing favorable guidelines and market expansion.

$ADPTMedAI 8/10

Adaptive Biotechnologies Q3 Earnings Call Highlights

Adaptive Biotechnologies (ADPT) reported Q3 2026 revenue of $83.9M, up 39% YoY, with GAAP net income of $2.8M. The company raised its full-year MRD revenue outlook to $276M-$286M. Clinical testing volume increased 46% YoY, and clonoSEQ tests grew 10% sequentially. Adaptive expects 42% clinical volume growth for the year and is pursuing Medicare reimbursement updates.